REAL WORLD OUTCOMES OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME- SINGLE CENTER EXPERIENCE FROM A RESOURCE LIMITED COUNTRY
Objective: In this study, we aim to evaluate the safety, efficacy and response rates of venetoclax and HMA combination therapy in patients with AML and MDS. This study provides outcomes from a tertiary care center in Pakistan, giving insights into the outcomes and impact of this therapeutic regimen...
Saved in:
| Main Author: | Maryam Khan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925001865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01) -
Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01) -
Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01) -
Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
by: Wenxiu Shu, et al.
Published: (2025-05-01) -
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)